New Once-Daily pill could simplify CAH treatment
NCT ID NCT03760835
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a once-daily dual-release hydrocortisone pill (Plenadren) works better than standard multiple-dose glucocorticoids for adults with congenital adrenal hyperplasia. The trial will enroll 150 adults and measure changes in cholesterol, blood sugar, weight, blood pressure, and quality of life. The goal is to see if the simpler dosing schedule improves health outcomes and daily living.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dual-release hydrocortisone (Plenadren)
What this could lead to
If it works, this could offer a more convenient once-daily treatment option that improves cholesterol, blood sugar, and quality of life for people with congenital adrenal hyperplasia.
What could go wrong
This is a Phase 4 open-label study, so results may be influenced by participants knowing which treatment they receive. The improvement over standard therapy may be modest, and not all patients may respond well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federico II University
RECRUITINGNaples, 80131, Italy
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••